- Home
- ROIV vs ICLR Comparison
ROIV vs ICLR Comparison
Compare ROIV & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | ICLR |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United Kingdom | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 14.3B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ICLR |
|---|---|---|
| Price | $21.67 | $184.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $21.94 | ★ $201.23 |
| AVG Volume (30 Days) | ★ 6.7M | 1.0M |
| Earning Date | 11-10-2025 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.47 |
| Revenue | $20,329,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $376.94 | $0.76 |
| P/E Ratio | ★ N/A | $24.96 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $125.10 |
| 52 Week High | $22.45 | $228.29 |
Technical Indicators
Market Signals| Indicator | ROIV | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 56.92 |
| Support Level | $20.14 | $178.80 |
| Resistance Level | $21.48 | $191.85 |
| Average True Range (ATR) | 0.71 | 7.83 |
| MACD | 0.00 | 0.92 |
| Stochastic Oscillator | 65.96 | 73.09 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.